Arteris, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2021. This is an annual filing; it does not provide standalone fourth-quarter financial results. Arteris supplies semiconductor system IP, including on-chip interconnect technology and IP deployment software.
Financial performance and liquidity
| Metric | 2021 | 2020 | Change |
|---|---|---|---|
| Revenue | $37.9 million | $31.8 million | Up 19% |
| Gross profit / margin | $34.1 million / 90% | $30.3 million / 95% | Margin down 5 percentage points |
| Operating expenses | $55.9 million | $34.1 million | Up 64% |
| Operating loss | $21.8 million | $3.8 million | Loss widened |
| Net loss | $23.4 million | $3.3 million | Loss widened |
| Net loss per share, basic and diluted | $1.06 | $0.19 | Loss per share increased |
| Cash from (used in) operations | $(0.8) million | $2.2 million | Down $3.0 million |
- Licensing, support and maintenance revenue rose 27% to $34.7 million. Variable royalties fell 24% to $2.6 million, chiefly because U.S. trade restrictions reduced a significant customer’s semiconductor production and shipments.
- Research and development expense increased 81% to $30.8 million; sales and marketing rose 20% to $11.7 million; general and administrative expense rose 82% to $13.4 million. Stock-based compensation increased to $5.5 million from $0.5 million, including $3.5 million recognized after IPO-related vesting conditions were met.
- Cash was $85.8 million at year-end, compared with $11.7 million a year earlier. Financing cash flow of $76.3 million was driven primarily by the October IPO and a $5.4 million common-stock issuance. Investing activities used $1.4 million.
- The $0.6 million term-loan balance was repaid at maturity in November 2021; the facility was not renewed. Vendor financing was $1.1 million at year-end. Current and noncurrent deferred revenue totaled $49.2 million.
- Management said cash and expected operating cash flows should cover working capital, capital expenditures and other liquidity needs for at least 12 months, while noting additional financing might be needed if resources prove insufficient.
Material changes and operating indicators
- Revenue increased, but losses expanded substantially as investment and public-company-related costs grew. Gross margin declined from 95% to 90%, partly alongside higher cost of revenue.
- Annual Contract Value was $47.4 million, up from $37.7 million; ACV plus trailing-twelve-month royalties and other revenue was $50.0 million, up from $41.9 million.
- Active Customers increased to 192 from 150; the annual average customer retention rate, excluding IP deployment solutions, was 94.6%. Design Starts rose to 86 from 57.
- Remaining Performance Obligations were $60.5 million, compared with $47.9 million. Separately, contracted unsatisfied or partially unsatisfied performance obligations were $49.3 million; the filing says $29.7 million, excluding non-cancelable flexible spending account commitments, was expected to be recognized over the next 12 months.
- The IPO closed in October 2021 at $14 per share, issuing 5.75 million shares and generating approximately $71.1 million net proceeds. Preferred shares converted into common stock.
- China accounted for 27.1% of 2021 revenue, down from 44.9% in 2020. International customers overall generated 56.9% of revenue, versus 67.1% in 2020. Intel accounted for 22.8% of 2021 revenue, according to the risk disclosures.
Outlook, risks and unusual items
- No specific numerical revenue or earnings guidance is provided. Management expects further net losses in the short term as it invests in the business; it expects R&D expense to rise in absolute terms and as a percentage of revenue in the near term.
- Management reported that 2021 results, cash flows and financial condition were not materially adversely affected by COVID-19, while noting the future impact remained uncertain.
- Arteris submitted a voluntary self-disclosure to the U.S. Bureau of Industry and Security in 2021 concerning potential export-control violations involving two Entity List parties. The matter remained under review; the company said a civil penalty or other penalty could not be ruled out, and the amount and likelihood were unclear.
- Key risks include customer and revenue concentration, lengthy design-to-production timelines, royalty volatility, semiconductor cyclicality and supply constraints, competition from internal and commercial alternatives, dependence on international markets and China, export restrictions, and the possibility of continued losses.
- Arteris was in preliminary discussions about a China joint venture when the filing was prepared. A subsequent-event disclosure says an agreement was signed on February 21, 2022, contemplating a 40.321% company interest and a five-year technology license; closing remained subject to conditions.
- There were no legal proceedings identified as expected to have a material adverse effect. The auditor issued an unqualified opinion on the financial statements; no auditor attestation of internal control was included under the transition relief for newly public companies.
Most important facts for investors to verify
- Whether rising ACV, customer counts and Design Starts convert into recognized revenue, royalties and positive operating cash flow.
- How much revenue and royalty exposure remains concentrated in individual customers and China, and how export restrictions affect future sales.
- Whether elevated R&D, sales and administrative spending—and IPO-related stock compensation—moderate as revenue grows.
- Cash burn, deferred revenue conversion, remaining performance obligations, and the timing and terms of vendor-financing and lease obligations.
- Status and final terms of the China joint venture, including the scope of licensed IP, governance, funding, regulatory approvals and closing conditions.
- Outcome of the BIS review of the export-control self-disclosure and any resulting penalties, restrictions or compliance obligations.